Literature DB >> 23921833

Association between depot medroxyprogesterone acetate (DMPA), physical activity and bone health.

Opeyemi O Babatunde1, Jacky J Forsyth.   

Abstract

Physical activity has been advocated for women in the hope of offsetting progestin-only contraceptive-related loss in bone mineral density. There is limited evidence for the beneficial effect of physical activity on bone health of hypo-oestrogenic premenopausal women. The aim of this cross-sectional study was to examine the relationship between physical activity and bone health [as measured by quantitative ultrasound (QUS)] of depot-medroxyprogesterone acetate (DMPA) users, and to investigate whether QUS measurements of DMPA users and non-users differed according to physical activity. Bone health of 48 DMPA users and 48 age-matched controls (22.83 ± 3.2 years) was assessed using calcaneal broadband ultrasound attenuation (BUA). Participants were categorised into low and high levels of physical activity based on their exposure to bone-loading exercise. Analysis of covariance was conducted to determine if QUS measurements of DMPA users and non-DMPA users differed within levels of bone-loading physical activity after controlling for body mass index. The duration of DMPA use ranged from 6 to 132 months. Participants' reference bone-loading exposure time averaged 3.3 ± 1.8 years. Data analysis revealed that DMPA users had significantly lower BUA by 6.54 dB/MHz (t (95) = -2.411, p = 0.018) compared to non-users of DMPA. Concurrently high levels of physical activity and DMPA use led to 1.996 dB/MHz decreases in BUA. A cycle of prolonged DMPA use and concurrent engagement in high levels of physical activity appears detrimental to bone health. It is suggested that the lack of oestrogen may counteract the effects of physical activity by inhibiting bone formation in response to mechanical bone-loading.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23921833     DOI: 10.1007/s00774-013-0497-y

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  34 in total

1.  Monitoring skeletal changes by radiological techniques.

Authors:  C C Glüer
Journal:  J Bone Miner Res       Date:  1999-11       Impact factor: 6.741

Review 2.  Depo-Provera and bone density.

Authors:  Babatunde A Gbolade
Journal:  J Fam Plann Reprod Health Care       Date:  2002-01

Review 3.  Use of depot medroxyprogesterone acetate contraception in adolescents.

Authors:  A J Davis
Journal:  J Reprod Med       Date:  1996-05       Impact factor: 0.142

4.  Effects on bone mineral density of low-dosed oral contraceptives compared to and combined with physical activity.

Authors:  M Hartard; P Bottermann; P Bartenstein; D Jeschke; M Schwaiger
Journal:  Contraception       Date:  1997-02       Impact factor: 3.375

5.  The impact of lifestyle factors on stress fractures in female Army recruits.

Authors:  J M Lappe; M R Stegman; R R Recker
Journal:  Osteoporos Int       Date:  2001       Impact factor: 4.507

6.  Bone mineral density loss and recovery during 48 months in first-time users of depot medroxyprogesterone acetate.

Authors:  M Kathleen Clark; Maryfran Sowers; Barcey Levy; Sara Nichols
Journal:  Fertil Steril       Date:  2006-09-25       Impact factor: 7.329

7.  Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls.

Authors:  Barbara A Cromer; Margaret Stager; Andrea Bonny; Rina Lazebnik; Ellen Rome; Julie Ziegler; Sara M Debanne
Journal:  J Adolesc Health       Date:  2004-12       Impact factor: 5.012

Review 8.  The use of depot-medroxyprogesterone acetate in contraception and its potential impact on skeletal health.

Authors:  Edith R Guilbert; Jacques P Brown; Andrew M Kaunitz; Marie-Soleil Wagner; Jocelyn Bérubé; Louise Charbonneau; Diane Francoeur; Andrée Gilbert; François Gilbert; Geneviève Roy; Vyta Senikas; Robert Jacob; Réal Morin
Journal:  Contraception       Date:  2009-01-15       Impact factor: 3.375

9.  Effects of Depot medroxyprogesterone acetate on bone density and bone metabolism before and after peak bone mass: a case-control study.

Authors:  Jennifer S Walsh; Richard Eastell; Nicola F A Peel
Journal:  J Clin Endocrinol Metab       Date:  2008-01-29       Impact factor: 5.958

10.  RETIRED: Canadian contraception consensus--update on Depot Medroxyprogesterone Acetate (dmpa).

Authors:  Amanda Black
Journal:  J Obstet Gynaecol Can       Date:  2006-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.